Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
At present, there are no relevant studies or reports on the effect of neoadjuvant
chemoradiation therapy combined with immunotherapy for MSS ultra-low rectal cancer. Studied
in this paper combin neoadjuvant chemoradiation with immune therapy, carry out "Multicenter
prospective randomized clinical trial of neoadjuvant chemoradiation therapy combined with
immunotherapy for MSS ultra-low rectal cancer" in order to provide a high-level
evidence-based medical evidence for ultra-low rectal cancer treatment and improve ultra-low
rectal cancer diagnosis and treatment effect.